Schedules of controlled substances

§1308.11 Schedule I.

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

(c) Opium Derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term “isomer” includes the optical, position and geometric isomers):

(e) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(g) Cannabimimetic agents. Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(h) Temporary listing of substances subject to emergency scheduling. Any material, compound, mixture or preparation which contains any quantity of the following substances:

[68 FR 14119, March 21, 2003; 69 FR 12796, March 18, 2004; 69 FR 58053, Sept. 29, 2004; 76 FR 11078, March 1, 2011; 76 FR 65374, Oct. 21, 2011; 77 FR 4235, Jan. 27, 2012; 78 FR 665, Jan. 4, 2013; 78 FR 21825, April 12, 2013; 78 FR 28738, May 16, 2013; 78 FR 68719, Nov. 15, 2013; 79 FR 1780, Jan. 10, 2014; 79 FR March 7, 2014; 80 FR 5047, Jan. 30, 2015; 80 FR 14844, March 20, 2015; 80 43285, July 17, 2015; 81 FR 6175, Feb. 5, 2016; 81 FR 22025, April 14, 2016; 81 FR 29145, May 11, 2016; 81 FR 29496, May 12, 2016; 81 FR 61133, Sept. 6, 2016; 81 FR 66184, Sept. 27, 2016; 81 FR 79393, Nov. 14, 2016; 81 FR 85877, Nov. 29, 2016; 81 FR 90196, Dec. 14, 2016; 81 FR 93599, Dec. 21, 2016; 82 FR 2218, Jan. 9, 2017; 82 FR 12177, March 1, 2017; 82 FR 17119, April 10, 2017; 82 FR 20547, May 3, 2017; 82 FR 26351, June 7, 2017; 82 FR 32457, July 14, 2017; 82 FR 47974, Oct. 16, 2017; 82 FR 49508, Oct. 26, 2017; 82 FR 51154, Nov. 3, 2017; 82 FR 58559, Dec. 13, 2017; 83 FR 472, Jan. 4, 2018; 83 FR 4584, Feb. 1, 2018; 83 FR 5191, Feb. 6, 2018; 83 FR 10368, March 9, 2018; 83 FR 17488, April 20, 2018; 83 FR 31882, July 10, 2018; 83 FR 44478, Aug. 31, 2018; 83 FR 61323, Nov. 29, 2018; 84 FR 15511, April 16, 2019; 84 FR 20023, May 8, 2019; 84 FR 20027, May 8, 2019; 84 FR 34297, July 18, 2019; 84 FR 57326, Oct. 25, 2019; 85 FR 4215, Jan. 24, 2020; 85 FR 17497, March 30, 2020; 85 FR 34607, June 8, 2020; 85 FR 51346, Aug. 20, 2020; 85 FR 51645, Aug. 21, 2020; 85 FR 62217, Oct. 2, 2020; 85 FR 73234, Nov. 25, 2020; 86 FR 11866, March 1, 2021; 86 FR 16667, March 31, 2021; 86 FR 22117, April 27, 2021; 86 FR 23606, May 4, 2021; 86 FR 30778, June 10, 2021; 86 FR 31429, June 14, 2021; 86 FR 32635, June 22, 2021; 86 FR 33510, June 26, 2021; 86 FR 44273, Aug. 12, 2021; 86 FR 60763, Nov. 4, 2021; 87 FR 20321, Apr. 7, 2022; 87 FR 21561, Apr. 12, 2022; 87 FR 32999, June 1, 2022; 86 FR 34169, June 6, 2022; 87 FR 68898, Nov. 17, 2022; 87 FR 70717, Nov. 21, 2022; 87 FR 71250, Nov. 22, 2022; 87 FR 75473, Dec. 9, 2022; 88 FR 13694, March 6, 2023; 88 FR 21102, Apr. 10, 2023; 88 FR 46073, July 19, 2023; 88 FR 48118, July 26, 2023; 88 FR 56469, Aug. 18, 2023; 88 FR 85108, Dec. 7, 2023; 88 FR 86045, Dec. 12, 2023; 89 FR 25517, Apr. 11 2024]

§1308.12 Schedule II

(a) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.

(b) Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β-naltrexol, naltrexone, and samidorphan, and their respective salts, but including the following:

(2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b)(1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include:

(i) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine;

(ii) [¹²³I]ioflupane; or

(iii) [¹⁸F]FP–CIT.

(5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy), 9670.

(c) Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

(d) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

(e) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(f) Hallucinogenic substances.

(g) Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Immediate precursor to amphetamine and methamphetamine:

(2) Immediate precursors to phenyclidine (PCP):

(3) Immediate precursor to fentanyl:

[72 FR 54208, Sept. 24, 2007; 77 FR 4235, Jan. 27, 2012; 80 FR 3470, Jan. 23, 2015; 80 FR 54718, Sept. 11, 2015; 81 FR 58839, Aug. 26, 2016; 82 FR 14820, March 23, 2017; 82 FR 45438, Sept. 29, 2017; 84 FR 2449, Feb. 7, 2019; 84 FR 41914, Aug. 16, 2019; 85 FR 4217, Jan. 24, 2020; 85 FR 21325, April 17, 2020; 85 FR 68753, Oct. 30, 2020; 86 FR 20286, April 19, 2021; 86 FR 30774, June 10, 2021; 87 FR 70717, Nov. 21, 2022]

§1308.13 Schedule III.

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled substances Code Number set forth opposite it.

(b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture or preparation containing:

or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

(2) Any suppository dosage form containing:

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.

Some trade or other names for a tiletaminezolazepan combination product: Telazol

Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone

Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon

(d) Nalorphine 9400.

(e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule:

(f) Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any substance meeting the definition of anabolic steroid as set forth in § 1300.01 of this chapter, including any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers (4000):

(1) 5α-androstan-3,17-dione;

(2) 5α-androstan-3,6,17-trione;

(3) 1-androstenediol (3β,17β-dihydroxy-5α-androst-1-ene);

(4) 1-androstenediol (3α,17β-dihydroxy-5α-androst-1-ene);

(5) 4-androstenediol (3β,17β-dihydroxy-androst-4-ene);

(6) 5-androstenediol (3β,17β-dihydroxy-androst-5-ene);

(7) 1-androstenedione (5α-androst-1-en-3,17-dione);

(8) 4-androstenedione (androst-4-en-3,17-dione);

(9) 5-androstenedione (androst-5-en-3,17-dione);

(10) bolasterone (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

(11) boldenone (17β-hydroxyandrost-1,4-diene-3-one);

(12) boldione (androsta-1,4-diene-3,17-dione);

(13) 6-bromo-androsta-1,4-diene-3,17-dione;

(14) 6-bromo-androstan-3,17-dione;

(15) calusterone (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

(16) 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;

(17) 4-chloro-17α-methyl-androst-4-ene-3β,17β-diol;

(18) 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;

(19) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;

(20) clostebol (4-chloro-17β-hydroxyandrost-4-en-3-one);

(21) dehydrochloromethyltestosterone (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one);

(22) desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) (a.k.a. “madol”);

(23) 4-dihydrotestosterone (17β-hydroxy-androstan-3-one);

(24) Δ1-dihydrotestosterone (a.k.a. “1-testosterone”) (17β-hydroxy-5α-androst-1-en-3-one);

(25) 3β,17β-dihydroxy-5α-androstane;

(26) 3α,17β-dihydroxy-5α-androstane;

(27) 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;

(28) drostanolone (17β-hydroxy-2α-methyl-5α-androstan-3-one);

(29) 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;

(30) estra-4,9,11-triene-3,17-dione;

(31) 13β-ethyl-17β-hydroxygon-4-en-3-one;

(32) ethylestrenol (17α-ethyl-17β-hydroxyestr-4-ene);

(33) fluoxymesterone (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one);

(34) formebolone (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one);

(35) furazabol (17α-methyl-17β-hydroxyandrostano[2,3-c]furazan);

(36) [3,2-c]furazan-5α-androstan-17β-ol;

(37) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;

(38) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one);

(39) 4-hydroxy-androst-4-ene-3,17-dione;

(40) 17β-hydroxy-androstano[2,3-d]isoxazole;

(41) 17β-hydroxy-androstano[3,2-c]isoxazole;

(42) 3β-hydroxy-estra-4,9,11-trien-17-one;

(43) 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one);

(44) mestanolone (17α-methyl-17β-hydroxy-5α-androstan-3-one);

(45) mesterolone (1α-methyl-17β-hydroxy-5α-androstan-3-one);

(46) methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one);

(47) methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene);

(48) methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one or 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one);

(49) methenolone (1-methyl-17β-hydroxy-5α-androst-1-en-3-one);

(50) 17α-methyl-androsta-1,4-diene-3,17β-diol;

(51) 17α-methyl-5α-androstan-17β-ol;

(52) 17α-methyl-androstan-3-hydroxyimine-17β-ol;

(53) 6α-methyl-androst-4-ene-3,17-dione;

(54) 17α-methyl-androst-2-ene-3,17β-diol;

(55) 17α-methyl-3β,17β-dihydroxy-5α-androstane;

(56) 17α-methyl-3α,17β-dihydroxy-5α-androstane;

(57) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;

(58) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one);

(59) methyldienolone (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);

(60) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (a.k.a. “17-α-methyl-1-testosterone”);

(61) methyltestosterone (17α-methyl-17β-hydroxyandrost-4-en-3-one);

(62) methyltrienolone (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one);

(63) mibolerone (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one);

(64) nandrolone (17β-hydroxyestr-4-en-3-one);

(65) 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4-ene);

(66) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-ene);

(67) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-ene);

(68) 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5-ene);

(69) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);

(70) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(71) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

(72) norbolethone (13β,17α-diethyl-17β-hydroxygon-4-en-3-one);

(73) norclostebol (4-chloro-17β-hydroxyestr-4-en-3-one);

(74) norethandrolone (17α-ethyl-17β-hydroxyestr-4-en-3-one);

(75) normethandrolone (17α-methyl-17β-hydroxyestr-4-en-3-one);

(76) oxandrolone (17α-methyl-17β-hydroxy-2-oxa-5α-androstan-3-one);

(77) oxymesterone (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);

(78) oxymetholone (17α-methyl-2-hydroxymethylene-17β-hydroxy-5α-androstan-3-one);

(79) prostanozol (17β-hydroxy-5α-androstano[3,2-c]pyrazole or [3,2-c]pyrazole-5α-androstan-17β-ol);

(80) [3,2-c]pyrazole-androst-4-en-17β-ol;

(81) stanozolol (17α-methyl-17β-hydroxy-5α-androst-2-eno[3,2-c]-pyrazole);

(82) stenbolone (17β-hydroxy-2-methyl-5α-androst-1-en-3-one);

(83) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

(84) testosterone (17β-hydroxyandrost-4-en-3-one);

(85) tetrahydrogestrinone (13β,17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one); and

(86) trenbolone (17β-hydroxyestr-4,9,11-trien-3-one).

(g) Hallucinogenic substances.

[67 FR 622370, Oct. 7, 2002; 70 FR 74653, Dec. 16, 2005; 71 FR 51115, Aug. 29, 2006: 72 FR 54226, Sep. 24, 2007; 77 FR 4236, Jan. 27, 2012; 78 FR 72016, Dec. 2, 2013; 79 FR 49682, Aug. 22, 2014; 88 FR 50040, Aug. 1, 2023]

§1308.14 Schedule IV.

(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(d) [Reserved]

(e) Lorcaserin. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(g) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:

[74 FR 51235, Oct. 6, 2009; 76 FR 77358, Dec. 12, 2011; 78 FR 26705, May 8, 2013; 79 FR 10989, Feb. 27, 2014; 79 FR 37629, July 2, 2014; 79 FR 51247, Aug. 28, 2014; 80 FR 69864, Nov. 12, 2015; 84 FR 27943, June 17, 2019; 84 FR 27947, June 17, 2019; 85 FR 19391, April 7, 2020; 85 FR 63019, Oct. 6, 2020; 86 FR 24492, May 7, 2021; 87 FR 20317, Apr. 7, 2022; 87 FR 78859, Dec. 23, 2022; 88 FR 74352, Oct. 31, 2023]

§1308.15 Schedule V.

(a) Schedule V shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section.

(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:

(1) [Reserved]

(c) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:

(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.

(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.

(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.

(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.

(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.

(6) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

(d) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(e) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

[81 FR 29491, May 12, 2016; 85 FR 5562, Jan. 31, 2020; 85 FR 13746, March 10, 2020; 87 FR 32966, June 1, 2022]